Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early virological response to combined antiviral therapy in chronic hepatitis C genotype 2 and 3
2004-005108-33Phase 4Active
- Sponsor
- AOU Città della Salute e della Scienza di Torino
- Start
- Feb 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of peginterferon alfa-2b and ribavirin in hepatitis C virus infection and hepatic failure (2 arms), sponsored by AOU Città della Salute e della Scienza di Torino. Primary endpoint: Sustained virological response. Started Feb 2007; status: active.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatitis C virus infectionhepatic failure
Beyond the preview
Go deeper on 2004-005108-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005108-33.